Advaita’s iPathwayGuide Provides a Cost-effective Alternative to Ingenuity Pathway Analysis (IPA) on Yet Another Continent
Summary
ANN ARBOR, Mich.--(BUSINESS WIRE)--Advaita Bioinformatics, the leader in the interpretation of high-throughput biomedical data, today announced a new distribution partnership with Inqaba Biotechnical Industries. He went on to say, "Advaita’s platform has everything our customers need to efficiently and rapidly extract profound insights from their data and at a fraction of the cost relative to competitor products, which is a great bonus. " Advaita’s platform helps principal investigators, core facilities, and bioinformatics teams analyze very large RNA-Seq or protein datasets and DNA-Seq variant data to find biomarkers, identify impacted pathways, and pinpoint putative mechanisms. Advaita’s proprietary algorithms modernize this process with solutions designed to provide superior results at a lower price, simplify collaboration across labs, and generate beautiful publication-ready graphics. Said Advaita CEO Sorin Draghici: “We are proud to partner with an innovative, industry-leading organization like Inqaba in order to expand our offering to yet another continent.